Clinical Report: The Role of Macrophage Migration Inhibitory Factor in Atrial Fibrillation

Overview

Macrophage migration inhibitory factor (MIF) plays a significant role in the pathophysiology of atrial fibrillation (AF) by influencing both electrical and structural remodeling. Elevated circulating MIF levels are associated with AF type and disease burden.

Background

Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia, affecting millions globally and significantly increasing the risk of stroke and heart failure. Understanding the molecular mechanisms underlying AF is crucial for developing effective therapeutic strategies.

Data Highlights

No numerical data available in the source material.

Key Findings

• MIF drives atrial electrical remodeling by promoting pro-inflammatory cytokine release and modulating ion channels.
• MIF contributes to structural remodeling and fibrosis through fibroblast activation and collagen deposition.
• Circulating MIF levels are independently associated with AF type and disease burden.
• Direct MIF inhibition has shown antiarrhythmic potential in animal models.

Clinical Implications

MIF may serve as a biomarker for assessing AF severity and risk of adverse outcomes.

Conclusion

MIF's involvement in AF pathophysiology highlights its potential as a biomarker. Further research is essential to elucidate its mechanisms.

Related Resources & Content

1. Basic Research in Cardiology, 2016 -- Interactions Between Macrophages and Atrial Myocytes in Atrial Fibrillation
2. Basic Research in Cardiology, 2023 -- Therapeutic Strategies Utilizing Macrophages for Treating Cardiovascular Disorders
3. Basic Research in Cardiology, 2020 -- Cardiac Resident Macrophages: Essential Regulators of Cardiac Physiology and Pathology
4. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
5. 2024 ESC Guidelines for the management of atrial fibrillation
6. Basic Research in Cardiology — Mechanisms at the Cellular and Mitochondrial Levels in Atrial Fibrillation
7. Association of inflammatory markers with clinical outcomes in atrial fibrillation: a meta-analysis
8. Atrial fibroblast–derived macrophage migration inhibitory factor
9. Macrophage Migration Inhibitory Factor in Atrial Fibrillation
10. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
11. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
12. Left atrial volume index and interleukin-6 as predictors for postoperative atrial fibrillation